ArticleClinical nephrology2025
The effect of finerenone on arterial stiffness in patients with diabetic kidney disease: A pilot study.
Article in Clinical nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with diabetic kidney disease (DKD) have an increased risk of not only renal, but also cardiovascular events. Finerenone is a novel, non-steroidal antagonist of the mineralocorticoid receptor that reduces albuminuria, protects kidney function, and improves cardiovascular outcomes. MATERIALS AND
methodsOur aim was to evaluate the impact of finerenone on arterial stiffness parameters following 6 months of treatment. Additionally, we aimed to assess its effects on kidney function, potassium level, albuminuria (urinary albumin-to-creatinine ratio (UACR)), and hydration status, as measured by lung ultrasound (B-lines) and bioimpedance spectroscopy (BIS). Statistical analysis was conducted using SPSS.
resultsWe included 25 patients, with the average age 63.8 ± 8.4 years (range 43 - 73 years). Serum potassium increased after 1 month of treatment (4.5 ± 0.4 vs. 4.3 ± 0.4 mmol/L at baseline, p = 0.017) and remained stable afterwards. Kidney function remained stable, and UACR decreased slightly, with the lowest value at 3 months (67.0 ± 97.7 vs. 82.6 ± 116.6 g/mol at baseline, p = 0.054). Carotid-femoral pulse wave velocity decreased from 12.0 ± 3.1 m/s at baseline to 10.9 ± 3.1 m/s (p = 0.015). No effect on blood pressure or the degree of BIS overhydration was noted. However, we found a decrease in the number of B-lines after 6 months of treatment (4.9 ± 5.5 vs. 7.4 ± 8.4 at baseline, p = 0.021).
conclusionOur findings indicate that after 6 months of treatment, finerenone led to a decrease in central arterial stiffness and interstitial lung water. Kidney function remained stable, no clinically significant hyperkalemia occurred.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.